Tag Archives: IPF

FLUIDDA’s IPF Catalyst Challenge Entry

FLUIDDA is excited to join the IPF Catalyst Challenge!

Functional Respiratory Imaging (FRI) is a very promising tool for early diagnosis, disease staging and progression and as a sensitive biomarker in drug development trials. As part of the challenge we would like to build a framework to enhance patient care through FRI because we believe that together with all stakeholders we can get closer to finding a cure for this terrible disease.

 

Introduction to Functional Respiratory Imaging (FRI) for Investors and Market Analysts

For those who cannot attend our event coming Thursday at Flanders House in New York, you are welcome to register for the Webcast via following link: https://attendee.gotowebinar.com/register/8186175617140384514       FLUIDDA is delighted to invite you to a dedicated session discussing her proprietary Functional Respiratory Imaging (FRI) technology and its application in drug and device… Continue Reading

FLUIDDA’s FRI technology will shine throughout ERS 2017

As the European Respiratory Society Conference is approaching rapidly, FLUIDDA is proud to announce that a total of 9 abstracts will be presented, highlighting the power of Functional Respiratory Imaging (FRI). FRI capabilities will be presented over a range of applications including: drug delivery optimization bronchodilation and non-invasive ventilation in COPD bronchoconstriction in asthma disease… Continue Reading

Study confirmed enhanced sensitivity of Functional Respiratory Imaging (FRI) compared to conventional lung function measures in IPF trial

” We were very impressed by the additional insights FRI brought to this clinical trial. The FRI data gave us confidence in the potential of this drug, supporting the signal observed in the lung function measurements. This type of information is very valuable when designing the next clinical trials for this compound.” Dr Piet Wigerinck, Chief… Continue Reading

FRI in IPF-PH paves the way for Phase IIb trial with INOpulse Device

“The U.S. Food and Drug Administration approved the design of a Phase 2b trial of INOpulse, a device that delivers nitric oxide, as a treatment for patients with pulmonary hypertension associated with lung disease. INOpulse’s developer, Bellerophon Therapeutics, said the sign-off came after a meeting with the FDA in June. In addition to the Phase 2b design, the… Continue Reading

FLUIDDA to present and exhibit at the IPF Summit in Boston, 21-23 Aug 2017

FLUIDDA’s CEO Dr. Jan De Backer will present at IPF Summit in Boston next month. Dr De Backer will discuss how using Functional Respiratory Imaging (FRI) in clinical trials has led to valuable insights into disease progression and treatment effects. Furthermore, the use of FRI, as an FDA supported drug development tool, will be discussed.… Continue Reading

Artificial Intelligence, Functional Respiratory Imaging and Lung Health: a triad for better respiratory care.

(This post first appeared on Pulse) Machine Learning and Artificial Intelligence in Healthcare require reliable data with low variability, accurately describing the disease state and progression If we would go by the ads we see on TV we would conclude that IBM Watson is the perfect husband, wife, boss, coworker. IBM Watson not only knows… Continue Reading

Fluidda NV

Groeningenlei 132

2550 Kontich

Belgium

BE 0877 160 706

Tel: +32/(0)3 450 87 20

Fax: +32/(0)3 450 87 29

info@fluidda.com

Fluidda NV

Groeningenlei 132

2550 Kontich

Belgium

BE 0877 160 706

Tel: +32/(0)3 450 87 20

Fax: +32/(0)3 450 87 29

info@fluidda.com

FLUIDDA, Inc

675 US Highway One
North Brunswick, NJ 08902
United States

FLUIDDA, Inc

675 US Highway One
North Brunswick, NJ 08902
United States

FLUIDDA India

Medical Imaging pvt ltd
A-95/96, DGP Nagar -2, Ambad
Nashik 422010
India

FLUIDDA India

Medical Imaging pvt ltd
A-95/96, DGP Nagar -2, Ambad
Nashik 422010
India

All content © FLUIDDA 2017